Skye Biosciences — Advancing Nimacimab In The Anti-Obesity Market
Searching for long-term methods to tackle obesity
Punit Dhillon, CEO of Skye Bioscience, tells In Vivo about the advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics
